Radiofrequency Ablation of Osteoid Osteomas: Analgesia and Patient Satisfaction in Long-term Follow-up

Authors
B. Gebauer1, F. Collettini1, C. Bruger1, K.-D. Schaser2, I. Melcher2, P.-U. Tunn3, F. Streitparth1

Affiliations
1 Department of Radiology, Charité – Universitätsmedizin Berlin
2 Center for Musculoskeletal Surgery, Charité – Universitätsmedizin Berlin
3 Department of Orthopaedic Oncology, HELIOS-Klinikum Berlin-Buch

Key words
- ablation procedures
- radiofrequency ablation
- osteoid osteoma
- complication
- patient satisfaction

Abstract

Purpose: To review the long term clinical outcomes in the treatment of osteoid osteoma (OO) using radiofrequency ablation (RFA).

Materials and Methods: Our retrospective study included 59 patients who were treated in the period from April 2001 to December 2012 due to a symptomatic OO using RFA. Here, the occurrence of complications and postoperative recurrence, as well as postoperative patient satisfaction were examined. Patients satisfaction was assessed by means of a telephone interview with the visual analogue scale (VAS).

Results: Mean follow-up was 50 months (2–116 months). The average size of the nidus was 6 mm (range 2–14 mm). After initial radiofrequency ablation 11.8 % (7/59) of patients showed a recurrence of symptoms. Symptoms could successfully be treated by a second ablation in 5 patients. Assisted success rate was therefore 96.6 % (57/59). The complication rate was 5.1 % (2 major and one minor complication). Furthermore we report a very high patient satisfaction and acceptance of therapy.

Conclusion: RFA is a very successful therapy of symptomatic OOs with a high patient satisfaction.

Key Points:
- Osteoid ostomas (OO) are rare benign bone tumors of the childhood and adolescence.
- Treatment of OOs with minimal-invasive radiofrequency ablation (RFA) shows a high patient satisfaction.
- RFA is by now the standard therapy of symptomatic OOs.

Zusammenfassung

Ziel: Ermittlung des klinischen Erfolgs und der Patientenzufriedenheit nach Radiofrequenzablation (RFA) von symptomatischen Osteoidosteomen (OO) im Langzeitverlauf.


Ergebnisse: Der Nachbeobachtungszeitraum erstreckte sich im Durchschnitt über 50 Monate (2–116 Monate). Die durchschnittliche Größe des Nidus lag bei 6 mm (2–14 mm). Die initiale Radiofrequenzablation zeigte in 11.8 % (7/59) ein Rezidiv der Schmerzsymptomatik, das bei 5 Patienten mittels einer zweiten Ablation erfolgreich behandelt werden konnte. Die assistierte Erfolgsrate war somit 96.6 % (57/59). Die Komplikationsrate lag bei 5.1 % (2 Major- und eine Minor-Komplikation). Darüber hinaus konnten wir eine sehr hohe Patientenzufriedenheit und Therapieakzeptanz feststellen.

Schlussfolgerung: Die RFA ist ein sehr erfolgreiches Therapieverfahren von symptomatischen Osteoidosteomen mit hoher Patientenzufriedenheit.
Introduction

Osteoid osteoma is a benign, osteogenic bone tumor that appears primarily in young patients in their 20s and 30s [1]. The nidus of the osteoid osteoma consists of immature bone and is rich in blood vessels and nerve cells. These nerve cells produce prostaglandins, in particular prostaglandin E2, presumably causing the characteristic nocturnal pains, which respond rapidly—within 20 to 30 minutes—to non-steroidal anti-inflammatory drugs (NSAIDs) [2]. Characteristic radiological signs of osteoid osteoma are the central, radiotransparent, partly ossifying nidus measuring a maximum of 15 to 20 millimeters and surrounded by a zone of reactive ossification [3]. Left untreated, osteoid osteomas exhibit both clinical and radiological natural regression. However, this process takes on average 6 years (range 2 to 15 years) [1, 4, 5]. NSAIDs not only alleviate the symptoms in patients with osteoid osteoma, but also accelerate the clinical regression of the symptoms to an average of 33 months (range 30 to 40 months) [6].

While the standard therapy for symptomatic osteoid osteoma used to be open resection of the nidus, in the last two decades thermal ablation of the nidus has steadily established itself as the standard therapy since first being described by Rosenthal et al. in 1992 [7, 8]. The present study used a standardized telephone interview to examine the long-term recurrence and complication rates following CT-guided thermoablation (RFA) of symptomatic osteoid osteoma.

Material and methods

Patients

The study included all consecutive patients who had been treated between April 2001 and December 2012. Standard imaging prior to therapy consisted of a conventional X-ray in two projections and non-contrast computed tomography (CT). For patients presenting the classic clinical and radiological criteria of an osteoid osteoma (age; nocturnal pains; rapid response to NSAIDs; sharply demarcated, cortical lytic lesion measuring a maximum of 20 mm in diameter, occasionally exhibiting central calcification; surrounded by cortical, osseous protrusion caused by ossification with soft tissue reaction, „CT vessel sign” or „vascular groove sign”) additional imaging or histological confirmations were not performed (Fig. 1) [9, 10]. Patients not satisfying these criteria either underwent additional imaging (contrast-enhanced magnetic resonance imaging (MRI) and/or bone scintigraphy) or had histological confirmation performed immediately prior to the CT-guided ablation.

Interventional therapy

All patients were informed of the available therapy options as well as the sequence of the intervention and the risks thereof. All ablations were performed under general anesthesia, since the puncture and the ablation of the osteoid osteoma are usually very painful for the patients. In all but one patient, the nidus was drilled open under CT-fluoroscopy. In this process either a 3–4 mm diameter hole was drilled through the nidus using an electrical orthopedic drill under CT-guidance, or, if the nidus was located at a shallow depth, there was a thin cortical bone layer or histological confirmation was desired, a bone punch biopsy was taken by the radiologist using a hand drill (11 G Präpa-Plus, Pflugbeil, Zorneding, Germany) or a battery-operated bone biopsy system (15G OnControl, VIDACARE, Shavano Park, Tx, USA) (Fig. 2). Afterwards, thermal ablation was performed using temperature-controlled radiofrequency ablation (RFA) (16G RITA StarBurst SDE, RITA Medical Systems, Mountain View, USA) with a target temperature of 60–90 °C at a maximum power of 90 Watts for 4–6 minutes.<0 The reduced temperature of 60 °C was used on patients in whom it was absolutely necessary to prevent thermal damage of the surrounding tissue given the proximity to critical neighboring structures (generally nerves). „Low temperature” ablation was used most frequently for ablating osteoid osteomas near the spinal column (Fig. 3).

Post-interventional management

After undergoing therapy, all patients were monitored while under full inpatient conditions. To check the success of ablation, contrast-enhanced MRI was performed on several patients as well as on any patient in whom recurrence or other complications were suspected.

Telephone interview

To ascertain the long-term clinical success of the treatment, a standardized telephone survey of all treated patients was
conducted between September 2011 and April 2013 (Table 1), focusing on the post-therapeutic absence of pain, satisfaction with therapy and subsequent RFA therapy in the case of recurrences. The study and patient survey received ethics approval.

**Definitions**

Initial success: Complete subsidence of pain symptoms without the use of anti-inflammatory medication within 1 month; Persisting pain: ongoing typical pain or use of anti-inflammatories 1 month following ablation; Recurrence: reappearance of typical symptoms following initial absence of pain; Assisted success rate: complete subsidence of typical pain symptoms following repeated ablation. Complications following ablation were classified according to the recommendations of the Society of Interventional Radiology (SIR) as minor- (A and B) and major- (C through F) complications [11, 12].
Results

Patients

In the period from April 2001 through December 2012, a total of 59 patients (39 [66%] male and 20 [34%] female) were included in the study. At the time of the diagnosis, average patient age was 22 years (4 – 55 years). The osteoid osteomas were primarily located in the lower extremities in 90% of cases, with the right femur being the most common location. Also included in the study were 4 patients with symptomatic osteoid osteomas near the spinal column, mainly in the vertebral body. Pre-interventional CT of the osteoid osteomas showed an average nidus diameter of 6 mm (range: 2 – 14 mm).<0>

Follow up

All patients underwent the intervention as an inpatient procedure, (while in theory the intervention could have been performed as an outpatient surgery, it currently cannot be billed as such in German, although it is being discussed). Whenever an ablation was performed on extremely athletic patients (competitive athletes), we recommended...
that they temporarily (approx. 4–6 weeks) restricted themselves from intense athletic activities. While a clinical follow-up examination was performed on all of the patients, medical imaging for the purpose of checking the success of ablation was not routinely performed, since the clinical symptoms of the patients were paramount. The average follow-up since RFA of the osteoid osteoma took place at 50 months (range 2–116 months).

**Technical success**

In all patients, the osteoid osteoma was successfully drilled manually or mechanically and ablated under CT-fluoroscopy during the first therapy session, thus yielding a technical success rate of 100%.

Of 59 patients, 56 were pain-free immediately following ablation as well as during the first month (initial success = 94.9%). In the case of 2 patients, further procedure is currently being discussed on an interdisciplinary basis, while in the case of the third patient other causes are presumably responsible for the residual pains. After initially being pain-free, 5 patients experienced a painful recurrence. In all 5 of these patients, contrast MRI performed at the time of the clinical recurrence showed a contrast enhancement in the area of the nidus. All 5 patients were successfully treated with secondary RFA and have remained pain-free long-term (Fig. 4). Residual pains appearing in any patient were attributed to recurrence of the initial RFA, yielding a total number of recurrences of \( n = 7 \) (11.9%).

**Complications**

One patient presented a soft tissue abscess 3 months following successful ablation, which had to be surgically removed. Two months following RFA, another patient fractured her tibia in the area of the osteoid osteoma when jumping from the horizontal bar during school sports (Fig. 5). These cases represent two major complications following RFA. A minimal loss of sensitivity in the area of the ablation site was documented in another patient, which later subsided. Thus 3 complications (2 major and one minor) were ascertained among the 59 patients, corresponding to a complication rate of 5.1%.

**Telephone interview**

The telephone interview was conducted from September 2011 through April 2013. Of the 59 patients, 6 could not be reached by telephone. The results of the telephone interview are summarized in Table 1, which reflects a very high level of patient satisfaction and therapy acceptance.

**Discussion**

The goal in treating osteoid osteoma is freeing the patient from his or her pain [13]. Traditionally, surgical therapeutic methods (e.g., “en block” resection, curettage) had been long regarded as the gold standard in treatment of osteoid osteoma, since they exhibited very high success rates between 88 and 100% and had been long established [14–17]. The disadvantage of open surgical resection is the dis-
In various studies covering a total of more than 1356 patients, it has been demonstrated that the treatment of osteoid osteoma with RFA yields a success rate of 90% following the first ablation with an average initial success rate of 92%.

In our study we achieve a technical success rate of 100% as well as an initial clinical success rate of 94.2% (2 patients with residual pain [VAS > 2]). All other patients had no (VAS = 0) or minimal residual pain (VAS ≤ 2). Over the long term, 5 additional patients underwent a second RFA due to painful recurrence. We classified all 7 patients as recurrence cases (7/59 = 11.8%).

Painful recurrences are the product of incomplete tumor ablation [21–24]. The largest studies have published recurrence rates of 0–35% (Table 2). Kjar et al. showed that the rate of recurrence was significantly higher for osteoid osteomas measuring more than 10 mm in diameter [25]. In our study we successfully treated 5 of the 7 recurrences with another round of RFA without having to switch to another treatment method (medication, surgery). For the remaining 2 recurrences, further procedure is currently being discussed.

According to Rosenthal et al., a comparison of the rates of recurrence for surgical therapy and RFA yields no significant difference (91 vs. 89%) [26]. However, RFA proved to be superior in treating symptomatic recurrence following surgical resection (100 vs. 90%) [27].

With regard to the safety of RFA in treating osteoid osteoma, multiple studies have shown RFA to be a safe method with a low rate of complications. The major studies on the use of RFA for osteoid osteoma presented above indicated a complication rate of only 3% (41/1217) with the most common complication being the appearance of skin burns [28–35]. In our study, we recorded two major complications (soft tissue abscess, post-interventional fracture). These complications have also been reported by other authors [25, 36]. Furthermore, one of our 59 patients experienced a minor complication in the form of a loss of sensitivity that spontaneously subsided within 2 weeks.

Due to the proximity to nervous structures, treating osteoid osteomas near the spinal column constitutes a special situation. However, multiple studies have shown that RFA is also a safe method of therapy for spinal osteoid osteomas [37, 38]. Both studies achieved absence of pain in 79% of cases following initial RFA. Nervous structures can be isolated and cooled using air or carbon dioxide (CO2), or can alternatively be displaced with glucose or sterile water [37]. If the space-occupying aspect of the osteoid osteoma results in a compression of the nerve root, then surgery is indicated for the osteoid osteoma [38].

With regard to therapy satisfaction and the subjective perception of pain, we positively established that all 53 surveyed patients were completely satisfied with RFA for the treatment of their osteoid osteoma. The patients also confirmed that they would undergo RFA at our hospital again for any potential recurrences. We assume that these results are also based on the fact that the patients became free of pain within a short time following treatment. In our opinion, the 100% patient satisfaction and the fact that all patients are currently pain-free are the strongest arguments for treating osteoid osteoma with RFA.

In the German DRG (Diagnosis-related groups) System, RFA of symptomatic osteoid osteoma (ICD-10 Code: D16.-, OPS-Code: 5–789.6 „Other surgeries on the bone: destruction through radiofrequency thermoablation, percutaneous“) is categorized under the collective DRG 128C („Other interventions on connective tissue“). Because OPS and DRG already cover bone drilling and the possibly necessary medical imaging, no higher classification is necessary. With an
effective cost weight of 0.844 (2012, only 0.792 in 2013) the hospital receives a revenue €2494 at a state-specific base rate of €2955 in 2012, meaning that the DRG revenue is significantly lower compared to that of RFA of liver or kidney tumors. While the RFA needles for treating osteoid osteoma are somewhat less expensive, costing approximately €800 – 900 (liver/kidney RFA needles cost approximately €1500), the additional expenses for general anesthesia must be taken into consideration. Another disadvantage of this classification in the DRG system is that the minimum length of stay for this DRG is two days, meaning that early discharge would entail considerable deductions. It is currently not possible to bill patients carrying public health insurance for outpatient surgery.

The key limitation of this study is its retrospective design that hinders the uniform collection of data. Despite the limitations, we can conclude that RFA is a safe, minimally invasive therapy option for the treatment of osteoid osteoma with a high initial success rate and a low rate of recurrence. Patients experiencing a painful recurrence of osteoid osteoma should be offered the option of a second radiofrequency ablation. Long-term patient satisfaction following RFA of osteoid osteomas is high.

Acknowledgement

This manuscript is dedicated to Professor Bernd Hamm for his 60th birthday.

Literatur


Table 2 Overview of the clinical results of radiofrequency ablation in symptomatic osteoid osteoma; selection criterion was study with > 20 patients; in case of multiple studies from the same institution, the most recent study or the study with the highest number of patients was selected; Studies were sorted by number of patients (N = patients; RFA = radiofrequency ablation; = not specified).

<table>
<thead>
<tr>
<th>Author, city, year</th>
<th>N</th>
<th>Method</th>
<th>Target temperature</th>
<th>Location</th>
<th>Initial success</th>
<th>Complications (absolute)</th>
<th>Average follow-up (in months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rimondi, Bologna, 2012 [39]</td>
<td>557</td>
<td>RFA</td>
<td>90 – 93 °C, 4 – 15 min.¹</td>
<td>peripheral</td>
<td>96 %</td>
<td>5</td>
<td>–</td>
</tr>
<tr>
<td>Rosenthal, Boston, 2003 [33]</td>
<td>117</td>
<td>RFA</td>
<td>90 °C, 6 min.</td>
<td>peripheral + vertebral body</td>
<td>91 %</td>
<td>2</td>
<td>&gt;24</td>
</tr>
<tr>
<td>Vanderschueren Leiden 2002 [34]</td>
<td>97</td>
<td>RFA</td>
<td>90 °C, 4 min.</td>
<td>peripheral + vertebral body</td>
<td>75 %</td>
<td>2</td>
<td>41</td>
</tr>
<tr>
<td>Rehnitz, Heidelberg, 2012 [40,41]</td>
<td>77</td>
<td>RFA</td>
<td>90 °C, 6,5 min.</td>
<td>peripheral + vertebral body</td>
<td>96 %</td>
<td>2</td>
<td>35.5</td>
</tr>
<tr>
<td>Cichon, Münster, 2006 [42]</td>
<td>74</td>
<td>RFA</td>
<td>90 °C, 4 – 6 min.</td>
<td>peripheral + vertebral body</td>
<td>88 %</td>
<td>1</td>
<td>49.9</td>
</tr>
<tr>
<td>Peyser, Jerusalem, 2007 [43]</td>
<td>51</td>
<td>RFA</td>
<td>60 – 90 °C, 5 – 7 min.</td>
<td>peripheral + vertebral body</td>
<td>98 %</td>
<td>1</td>
<td>24</td>
</tr>
<tr>
<td>Jankharia, Mumbai, 2009 [44]</td>
<td>40</td>
<td>RFA</td>
<td>90 °C, 5 min.</td>
<td>peripheral</td>
<td>95 %</td>
<td>2</td>
<td>8</td>
</tr>
<tr>
<td>Hoffmann, Munich, 2010 [36]</td>
<td>39</td>
<td>RFA</td>
<td>80 – 95 °C, 6 – 8 min.</td>
<td>peripheral + vertebral body</td>
<td>92 %</td>
<td>3</td>
<td>30.5</td>
</tr>
<tr>
<td>Cioni, Pisa, 2004 [45]</td>
<td>38</td>
<td>RFA</td>
<td>85 – 90 °C, 4 – 5 min.</td>
<td>peripheral</td>
<td>79 %</td>
<td>2</td>
<td>35.5</td>
</tr>
<tr>
<td>Neumann, Salzburg, 2011 [46]</td>
<td>33</td>
<td>RFA</td>
<td>95 – 100 °C, 1,5 min.</td>
<td>peripheral</td>
<td>97 %</td>
<td>–</td>
<td>92</td>
</tr>
<tr>
<td>Sung, Seoul, 2009 [47]</td>
<td>28</td>
<td>RFA</td>
<td>80 – 90 °C, 3 – 9 min.</td>
<td>peripheral</td>
<td>82 %</td>
<td>1</td>
<td>41.1</td>
</tr>
<tr>
<td>Kjar, Melbourne, 2006 [25]</td>
<td>24</td>
<td>RFA</td>
<td>90 °C, 4 min.</td>
<td>peripheral</td>
<td>65 %</td>
<td>–</td>
<td>26</td>
</tr>
<tr>
<td>Vanderschueren Leiden, 2009 [38]</td>
<td>24</td>
<td>RFA</td>
<td>90 °C, 4 min.</td>
<td>vertebral body</td>
<td>79 %</td>
<td>–</td>
<td>72 %</td>
</tr>
<tr>
<td>Ockendon, Oswestry 2011 [48]</td>
<td>23</td>
<td>RFA</td>
<td>90 °C, 4 min.</td>
<td>peripheral</td>
<td>96 %</td>
<td>–</td>
<td>3.3</td>
</tr>
<tr>
<td>Donkol, Cairo 2008 [29]</td>
<td>23</td>
<td>RFA</td>
<td>90 °C, 4,5 min.</td>
<td>peripheral</td>
<td>91 %</td>
<td>3</td>
<td>28</td>
</tr>
<tr>
<td>Mylona, Athens, 2010 [49]</td>
<td>23</td>
<td>RFA</td>
<td>80 – 110 °C, 8 – 10 min.</td>
<td>peripheral + vertebral body</td>
<td>91 %</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Ghanem, Beirut, 2003 [50]</td>
<td>23</td>
<td>RFA</td>
<td></td>
<td>peripheral</td>
<td>100 %</td>
<td>3</td>
<td>42</td>
</tr>
<tr>
<td>Schmidt-D, Tübingen, 2011 [51]</td>
<td>23</td>
<td>RFA</td>
<td>60 – 90 °C, 4 – 6 min.</td>
<td>peripheral</td>
<td>100 %</td>
<td>8</td>
<td>75.9</td>
</tr>
<tr>
<td>Mastrantuono, Turin, 2005 [52]</td>
<td>21</td>
<td>RFA</td>
<td>85 – 90 °C</td>
<td>peripheral</td>
<td>100 %</td>
<td>–</td>
<td>11.1</td>
</tr>
<tr>
<td>Kyriakopoulos, Athens, 2007 [53]</td>
<td>21</td>
<td>RFA</td>
<td>90 °C, 3 × 2 min.</td>
<td>peripheral</td>
<td>100 %</td>
<td>–</td>
<td>29</td>
</tr>
<tr>
<td>Total</td>
<td>1356</td>
<td></td>
<td></td>
<td></td>
<td>92 %</td>
<td>(1247/1356)</td>
<td>2.9 % (35/1187)</td>
</tr>
</tbody>
</table>

¹ A group (N = 68) with 90 – 93 °C for 4 minutes and a second group (N = 489) with 60 °C for 2 minutes followed by ablation with 90 – 93 °C for 14–15 minutes.


44 jankharia B, burute N. Percutaneous radiofrequency ablation for osteoid osteoma: How we do it. The indian journal of radiology & imaging 2009; 19: 36 – 42


